Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gene expression test to quantify the likelihood of obstructive CAD in patients with stable chest pain
Subscribe to our email newsletter
CardioDx, a cardiovascular genomic diagnostics company, has completed its multicenter validation study for Corus CAD. It is a gene expression test to quantify the likelihood of obstructive coronary artery disease (CAD) in patients with stable chest pain. The company expects to present results of the study by the end of 2009, and will publish the results in 2010.
According to the company, Corus CAD is a clinically validated genomic test that integrates the expression levels of 23 genes and other patient characteristics to assess obstructive CAD.
The test is intended to be used in an outpatient setting with clinically stable, non-diabetic patients who present with chest pain or who have a high risk of coronary artery disease, but without previously diagnosed myocardial infarction (heart attack) or prior revascularization procedure.
CardioDx claims that Corus CAD is convenient and safe, and only requires a standard blood draw procedure. The test is expected to yield an objective result delivered to the physician in the form of a numeric score, that quantifies the likelihood that a patient with stable chest pain has obstructive CAD.
Following completion of the validation study, the company has made Corus CAD available in nine states initially, with broader availability expected in 2010.
David Levison, CEO of CardioDx, said: Completing the validation study for Corus CAD marks a major milestone for CardioDx. Our focus now turns to further developing the clinical and economic evidence needed to increase patient access to the unique benefits of Corus CAD.
Our decision to develop Corus CAD was derived from many physician interactions in which they stressed the importance of and current challenges with effectively assessing obstructive CAD in patients with stable chest pain. We envision that a non-invasive, objective, easy-to-use test such as Corus CAD will empower physicians to more confidently identify which of these patients may have obstructive CAD, he added.